M. Miravitlles (Barcelona, Spain), A. Anzueto (San Antonio, United States of America)
Late-breaking abstract: Moxifloxacin (MXF) vs amoxicillin/clavulanic acid (AMC) in acute exacerbations of COPD (AECOPD): Results of a large clinical trial with a novel endpoint
R. Wilson, A. Anzueto, M. Miravitlles, P. Arvis, J. Alder, D. Haverstock, M. Trajanovic, S. Sethi (London, United Kingdom; San Antonio, Montville, Buffalo, United States Of America; Barcelona, Spain; Loos, France; Toronto, Canada)
|   |
Rhinovirus infection induces secondary bacterial infection in COPD
P. Mallia, J. Footitt, R. Sotero, A. Jepson, G. Oleszkiewicz, J. Aniscenko, O. M. Kon, P. Alberto, S. Johnston, G. Pelaia (London, United Kingdom; Ferrara, Catanzaro, Italy)
|  |
Predictors of poor outcome in severe hospitalised COPD exacerbations
Z. Matkovic, M. Miravitlles, N. Soler, A. Huerta, R. Domingo, A. Gabarrus, A. Torres (Barcelona, Spain)
| |
Human respiratory epithelial cells acquire a long-lasting antiviral condition when exposed to interferon beta
G. Gaajetaan, G. Grauls, C. Bruggeman, F. Stassen (Maastricht, Netherlands)
| |
Rhinovirus infection upregulates pentraxin-3 in smokers and COPD patients
J. Footitt, P. Mallia, S. Rosa, M. B. Trujillo-Torralbo, T. Kebadze, M. Contoli, A. Papi, O. M. Kon, R. Maselli, S. Johnston (London, United Kingdom; Ferrara, Catanzaro, Italy)
| |
Metagenomic analysis of lower airway microbial diversity in patients with chronic pulmonary disease
E. Monso, R. Cabrera, A. Moya, A. Mira, M. Garcia, X. Pomares, J. M. Antó (Sabadell, Valencia, Barcelona, Spain)
| |
Value of galactomannan in bronchoalveolar lavage fluid for invasive pulmonary aspergillosis in critically ill chronic obstructive pulmonary disease
L. Ding, Y. He, F. Li, Q. Zhan (Beijing, China)
| |